The utility of splicing factor SRSF1 in gliomas grading: A meta-analysis

##plugins.themes.academic_pro.article.sidebar##

Published Aug 27, 2024
https://doi.org/10.62438/tunismed.v102i9.4954
Download
pdf
Vol. 102 No. 9 (2024): Tunis Med sept 2024

##plugins.themes.academic_pro.article.main##

Mona Mlika
Department of Pathology,Trauma and Major Burn Center Ben Arous, Faculty of Medicine of Tunis ,University of Tunis El Manar. Tunisia
Mohamed Majdi Zorgati
Biology Department. Military Hospital. Doha. Qatar
Aymen Makhlouf
Pathology Department, Traumatology and Burn Center . Ben Arous - Tunisia
Faouzi Mezni
University of Tunis El Manar. Faculty of Medicine of Tunis, Tunisia

Abstract

Introduction: The grading of glial tumors is based on morphological and sometimes on molecular features. Many markers have been assessed in order to grade the glial tumours without a real consensus. Some authors reported that SRSF1, a spiling factor, presents an expression correlated to the tumours grades.


Aim: In this study, we aimed to assess the utility of the SRSF1 into the grading of gliomas based on its immunohistochemical expression.


Methods: The authors conducted a meta-analysis under the PRISMA guidelines during a 10-year-period (2013-2023). The Meta-Disc software 5.4 (free version) was used. Q test and I2 statistics were carried out to explore the heterogeneity among studies. Meta-regression was performed in case of significant heterogeneity. Publication bias was assessed using the  funnel plot test and the Egger’s test (free version JASP).


Results: According to the inclusion criteria, 4 studies from 193 articles were included. The pooled SEN, SPE and DOR accounted respectively for 0.592, 0.565 and 1.852. The AUC was estimated to 0.558 suggesting a bad diagnostic accuracy. The heterogeneity in the pooled SEN and SPE was statistically significant. The meta-regression analysis focusing on the technique used, the clones, the dilution, the interpretation technique revealed no covariate factors (P>0.05).


Conclusion: Even if this meta-analysis highlighted the absence of a real diagnostic utility of the SRSF1 in grading the glial tumours, the heterogeneity revealed reinforces the need for more prospective studies performed according to the quality assessment criteria.

Keywords:

SRSF1 antibody, glial tumours, World Health Organization, splicing factors

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021 Aug 1;23(8):1231–51.
  2. Guo X, Gu L, Li Y, Zheng Z, Chen W, Wang Y, et al. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol. 2023;13.
  3. Du P, Wu X, Liu X, Chen J, Cao A, Geng D. Establishment of a Prediction Model Based on Preoperative MRI Radiomics for Diffuse Astrocytic Glioma, IDH-Wildtype, with Molecular Features of Glioblastoma. Cancers (Basel). 2023 Oct 1;15(20).
  4. Pytlarz M, Wojnicki K, Pilanc P, Kaminska B, Crimi A. Deep Learning Glioma Grading with the Tumor Microenvironment Analysis Protocol for Comprehensive Learning, Discovering, and Quantifying Microenvironmental Features. Journal of Imaging Informatics in Medicine [Internet]. 2024 Feb 27; Available from: https://link.springer.com/10.1007/s10278-024-01008-x
  5. Zhou X, Wang R, Li X, Yu L, Hua D, Sun C, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. Journal of Clinical Investigation. 2019 Feb 1;129(2):676–93.
  6. Barbagallo D, Caponnetto A, Brex D, Mirabella F, Barbagallo C, Lauretta G, et al. CircSMARCA5 regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1. Cancers (Basel). 2019 Feb 1;11(2).
  7. Zhou X, Li X, Yu L, Wang R, Hua D, Shi C, et al. The RNA-binding protein SRSF1 is a key cell cycle regulator via stabilizing NEAT1 in glioma. International Journal of Biochemistry and Cell Biology. 2019 Aug 1;113:75–86.
  8. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; Expression changes and driver mutations of splicing factor genes. Vol. 35, Oncogene. Nature Publishing Group; 2016. p. 2413–27.
  9. Barbagallo D, Caponnetto A, Cirnigliaro M, Brex D, Barbagallo C, D’Angeli F, et al. CircSMARCA5 inhibits migration of glioblastoma multiforme cells by regulating a molecular axis involving splicing factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018 Feb 6;19(2).
  10. Fuentes-Fayos AC, Vazquez-Borrego MC, Jimenez-Vacas JM, Bejarano L, Pedraza-Arevalo S, Lopez FL, et al. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: Oncogenic role of SRSF3. Brain. 2021;143(11):3273–93.
  11. Lo Giudice A, Asmundo MG, Broggi G, Cimino S, Morgia G, Di Trapani E, et al. The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. Vol. 12, Applied Sciences (Switzerland). MDPI; 2022.
  12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021 Dec 1;10(1).
  13. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies [Internet]. 2011. Available from: www.annals.org
  14. Ye LJ, Xu KM, Bai G, Yuan J, Ran FM. SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma. Oncol Lett. 2023 Aug 1;26(2).
  15. Broggi G, Salvatorelli L, Barbagallo D, Certo F, Altieri R, Tirrò E, et al. Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas. Cancers (Basel). 2021 May 1;13(9).
  16. Broggi G, Ieni A, Russo D, Varricchio S, Puzzo L, Russo A, et al. The Macro-Autophagy-Related Protein Beclin-1 Immunohistochemical Expression Correlates With Tumor Cell Type and Clinical Behavior of Uveal Melanoma. Front Oncol. 2020 Nov 20;10.
  17. Zhao J, Jiang Y, Zhang H, Zhou J, Chen L, Li H, et al. The SRSF1/circATP5B/miR-185-5p/HOXB5 feedback loop regulates the proliferation of glioma stem cells via the IL6-mediated JAK2/STAT3 signaling pathway. Journal of Experimental and Clinical Cancer Research. 2021 Dec 1;40(1).
  18. Barbagallo D, Caponnetto A, Barbagallo C, Battaglia R, Mirabella F, Brex D, et al. The gaugaa motif is responsible for the binding between circsmarca5 and srsf1 and related downstream effects on glioblastoma multiforme cell migration and angiogenic potential. Int J Mol Sci. 2021 Feb 2;22(4):1–16.
  19. Amin EM, Oltean S, Hua J, Gammons MVR, Hamdollah-Zadeh M, Welsh GI, et al. WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing. Cancer Cell. 2011;20(6):768–80.
  20. Giannakouros T, Nikolakaki E, Mylonis I, Georgatsou E. Serine-arginine protein kinases: A small protein kinase family with a large cellular presence. FEBS Journal. 2011 Feb;278(4):570–86.
  21. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: A novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry. 2010 Feb 19;285(8):5532–40.
  22. Graveley BR, Maniatis T. Arginine/Serine-Rich Domains of SR Proteins can function as activators of pre-mRNA splicing. Mol Cell. 1998;1:765–71.
  23. Fu Y, Huang B, Shi Z, Han J, Wang Y, Huangfu J, et al. SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing β-catenin biosynthesis. EMBO Mol Med. 2013 May;5(5):737–50.
  24. Cantley LC. The phosphoinositide 3-kinase pathway. Vol. 296, Science. 2002. p. 1655–7.
  25. Yang K, Tong L, Li K, Zhou Y, Xiao J. A SRSF1 self-binding mechanism restrains Mir505-3p from inhibiting proliferation of neural tumor cell lines. Anticancer Drugs. 2018 Jan 1;29(1):40–9.
  26. Jurica MS, Moore MJ. Review Pre-mRNA Splicing: Awash in a Sea of Proteins. Mol Cell. 2003;12:5–14.
  27. Dziri C. Evaluation of heterogeneity in meta-analysis. Colorectal Dis. 2023 May;25(5):1037-1038.
  28. Dziri C. How to assess heterogeneity for a meta-analysis? Tunis Med. 2022 Mai;100(5):353.